The procedure with the system can be completed within an hour. Credit: Dmitry Kalinovsky / Shutterstock.com.

Nectero Medical has secured fast-track designation from the US Food and Drug Administration (FDA) for its Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST) system.

The single-use endovascular system is intended for the treatment of patients with infrarenal abdominal aortic aneurysms (AAAs) with a maximum diameter of 3.5cm–5.0cm.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Nectero EAST consists of a stabiliser mixture containing pentagalloyl glucose (PGG) and a dual-balloon delivery catheter.

The system administers PGG locally to the aneurysmal wall, where it attaches to elastin and collagen, strengthening the aortic vessel wall and lowering further degradation risk.

Designed to finish within an hour, the procedure does not need any specialised tools and leaves no permanent implant.

Furthermore, it does not prevent future interventions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company is commencing a randomised, controlled Phase II/III trial (stAAAble) to assess the safety and effectiveness of Nectero EAST.

Nectero Medical president and CEO Jack Springer said: “This designation reinforces Nectero Medical’s belief that the Nectero EAST System has the potential to address a large segment of patients who suffer from a serious progressive disease with no proven treatment options.

“Available therapies are reserved primarily for patients who fall into the highest-risk category.

“We are proud to be advancing a treatment that has the potential to impact so many lives and are extremely pleased that the FDA acknowledged this through our designation.”

More than one million people in the US are anticipated to live with AAA and approximately 60,000 undergo treatment for this condition each year. The complications of AAA result in roughly 10,000 deaths annually in the country.